{"symbol":"AMGN","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"AMC","status":"upcoming","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q2-2026","preBrief":{"companySnapshot":"Amgen Inc. is a biotechnology company that develops and manufactures innovative therapies to treat serious illnesses. Operating in the Health Care sector, Amgen focuses on areas like oncology, cardiovascular disease, and inflammation, making it a key player in addressing significant health challenges.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a crucial indicator of the company's profitability and performance this quarter.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth will provide insight into the demand for Amgen's products and overall business health.","consensus":"N/A"},{"name":"Product Pipeline Updates","why":"Updates on new drugs or therapies in development can significantly impact future revenue potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by nearly 9%. The stock reacted positively, gaining 2.43% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Overall, analysts expect Amgen to continue its trend of beating EPS estimates, given its strong historical performance.","bullCase":"If Amgen can maintain its momentum and deliver strong results, it may see significant stock appreciation, especially if new product developments are announced.","bearCase":"Conversely, if earnings fall short of expectations or if there are negative updates regarding its product pipeline, the stock could face downward pressure."},"optionsSignal":{"impliedMove":"13.36%","context":"The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+8.88%","reaction":"+2.43%"},{"quarter":"Q4-2025","epsSurprise":"+11.18%","reaction":"-1.77%"},{"quarter":"Q3-2025","epsSurprise":"+12.75%","reaction":"+0.13%"},{"quarter":"Q2-2025","epsSurprise":"+15.61%","reaction":"-0.62%"},{"quarter":"Q1-2025","epsSurprise":"+17.85%","reaction":"-2.45%"}],"pivotalQuestions":[{"question":"What will be the EPS for Q2-2026?","whyItMatters":"Given Amgen's history of exceeding EPS estimates, this number will be critical in determining market sentiment post-earnings."},{"question":"What updates will be provided on the product pipeline?","whyItMatters":"Investors will closely watch for any news on new therapies or drugs, as this could significantly influence future revenue."}],"thesisBreakLevels":{"bullTrigger":"A reported EPS exceeding $5.50 would confirm the bullish outlook.","bearTrigger":"An EPS below $4.80 would suggest a bearish trend.","context":"The market is currently weighing Amgen's ability to sustain its earnings growth against potential challenges in its product pipeline."},"scenarioPlaybook":{"beatAndRaise":"If Amgen beats expectations, history suggests the stock could rise by around 0.72%, confirming the company's strong performance.","inLineCautious":"If results are in line but management provides cautious commentary, the stock may see muted movement as investors reassess their outlook.","miss":"Should the company miss earnings expectations, history suggests a potential decline of around 1.09%, which could raise concerns about future growth."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"X of Y (Z%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.5%, with a raw directional average of +0.7% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Amgen's potential for strong EPS growth due to its robust product pipeline and recent successful launches.","supportingPoints":["Amgen has consistently beaten EPS estimates, indicating strong operational efficiency.","The options market is pricing in a significant move, suggesting that investors expect volatility based on upcoming developments."],"riskToConsensus":"If Amgen's new product launches show stronger-than-expected demand, it could significantly alter the earnings outlook."},"whatToListenFor":["Any commentary on the success of recent drug launches.","Updates on the status of drugs in the pipeline.","Insights into market competition and how Amgen plans to respond.","Management's outlook on revenue growth for the upcoming quarters.","Any changes in guidance or strategic direction."],"metaDescription":"Amgen (AMGN) reports Q2 2026 earnings August 4. Investors are keenly watching for EPS and product pipeline updates."}}